+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Parkinson's Disease - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 142 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 4330868

This ‘Parkinson's Disease - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Parkinson's disease, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Parkinson's Disease Understanding

Parkinson's disease is a progressive disorder caused by the degeneration of nerve cells in the part of the brain called the substantia nigra and primarily affects movement. The motor symptoms of Parkinson's disease include tremors, bradykinesia (slowness of movement), rigidity, and postural instability, while the non-motor symptoms may include cognitive impairment, mood disorders, sleep disturbances, and autonomic dysfunction. These symptoms can severely affect a patient's quality of life if uncontrolled. Additionally, caregiver burden is significant due to the progressive nature of the disease.

The cause of Parkinson's disease remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. While men are slightly more susceptible than women, it typically affects individuals over the age of 60, but early-onset cases also occur.

The primary pathology is the degeneration of dopamine-producing neurons in the substantia nigra. Moreover, the accumulation of misfolded alpha-synuclein protein in the brain forms Lewy bodies, a hallmark of Parkinson's disease. Generally, there are five stages of Parkinson's disease: Stage I, Stage II, Stage III, Stage IV, and Stage V. Stage I has mild symptoms and minimal or no functional impairment, Stage II has bilateral symptoms and minimal impairment, Stage III has impaired balance with moderate functional impairment, Stage IV has severe symptoms with limited mobility, and Stage V is an advanced disease where individuals are bedridden and need assistance.

Parkinson's Disease Diagnosis

Diagnosis of Parkinson's is primarily clinical and is based on the presence of characteristic motor and non-motor symptoms. However, there is no definitive test for Parkinson's, so the diagnosis is primarily based on medical history, symptoms, and a physical examination. Diagnosis is also particularly difficult in its early stages and requires a skilled practitioner to confirm the disease. To avoid misdiagnosis, consultation with a movement disorder specialist (MDS) is recommended.

DaTscan, an imaging test, assists in confirming the diagnosis by assessing dopamine levels in the brain. MRI may be used to exclude other causes. Additionally, advancements in neuroimaging studies, including transcranial Doppler ultrasonography, PET, single-photon emission computed tomography (SPECT), morphometric MRI studies, tractography, functional MRI, and perfusion imaging, are being used to differentiate idiopathic Parkinson's disease from other parkinsonian disorders. Radionuclide imaging modalities like PET and SPECT, using a dopamine transporter ligand, have become the best approach to assess dopamine metabolism and deficiency.

Parkinson's Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Parkinson's Disease Detailed Epidemiology Segmentation

  • In 2022, there were approximately 2,539,400 diagnosed prevalent cases of Parkinson's disease in the 7MM. The US accounted for nearly 45% of the total diagnosed prevalent cases of Parkinson's disease in the 7MM.
  • the publisher's epidemiology model for Parkinson's disease estimates that in the US, nearly 660,458 cases and 491,736 cases were contributed by males and females, respectively, in 2022. These cases are expected to increase by 2032, with the disease being more prevalent in males than females.
  • As per the report estimates, in 2022, in the US, approximately 18,870 cases were diagnosed with Parkinson's disease in the age group =49 years, nearly 204,243 cases in 50-64 years, around 427,355 cases in 65-74 years, and approximately 501,726 cases in =75 years. By 2032, the cases in different age groups are expected to increase.
  • Among EU4 and the UK, there were approximately 1,185,570 diagnosed prevalent cases of Parkinson's disease. Germany accounted for the highest number of Parkinson's disease cases, with nearly 454,448 cases, while Italy accounted for the least diagnosed prevalent cases of Parkinson's disease in 2022.
  • In 2022, in EU4 and the UK, the highest diagnosed prevalent cases of Parkinson's were found in Stage II with approximately 388,499 cases, followed by Stage III with nearly 384,960 cases, Stage IV with around 208,042 cases, Stage I with nearly 153,164 cases, and Stage V with approximately 50,904 cases, The stage-specific diagnosed prevalent cases of Parkinson's disease are expected to change by 2032.
  • In 2022, among the 7MM, Japan accounted for nearly 8% of the diagnosed prevalent cases of Parkinson's disease. The cases are estimated to increase during the forecast period.
  • In Japan, males diagnosed with Parkinson's disease are higher in number than females. In 2022, there were approximately 105,583 male cases, while around 96,053 cases were among the female population.

Scope of the Report

  • The report covers a descriptive overview of Parkinson's disease, explaining its symptoms, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • The report assesses the disease risk and burden of Parkinson's disease.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease.

Report Highlights

  • Ten years forecast of Parkinson's disease
  • The 7MM Coverage
  • Total Diagnosed Prevalent Cases of Parkinson's disease
  • Gender-specific Diagnosed Prevalent Cases of Parkinson's disease
  • Age-specific Diagnosed Prevalent Cases of Parkinson's disease
  • Stage-specific Diagnosed Prevalent Cases of Parkinson's disease

Key Questions Answered

  • What are the disease risks and burdens of Parkinson's disease?
  • What is the historical Parkinson's disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • What would be the forecasted patient pool of Parkinson's disease at the 7MM level?
  • What growth opportunities will be across the 7MM concerning the patient population with Parkinson's disease?
  • Which country would have the highest diagnosed prevalent population of Parkinson's disease among the countries mentioned above during the forecast period (2023-2032)?
  • At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy

The Parkinson's disease report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's disease epidemiology forecast.
  • The Parkinson's disease epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Parkinson's disease epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of Disease by Segmentation
  • Factors Driving Growth in a Specific Patient Population

Geographies Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2019-2032

Table of Contents

1. Key Insights2. Report Introduction
3. Parkinson’s Disease Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Parkinson’s disease in 2019
3.2. Patient Share (%) Distribution of Parkinson’s Disease in 2032
4. Methodology of Parkinson’s Disease Epidemiology5. Executive Summary of Parkinson’s Disease
6. Disease Background and Overview
6.1. Introduction
6.2. Classification
6.3. Signs and Symptoms
6.4. Risk Factors
6.5. Pathophysiology
6.6. Diagnosis
6.6.1. Biomarker
6.6.2. Diagnostic Guidelines
6.6.2.1. American Academy of Family Physicians
6.6.2.2. European Federation of Neurological Societies/Movement Disorder Society- European Section (EFNS/MDS-ES) Recommendations for the Diagnosis of Parkinson’s Disease
6.6.2.3. The National Institute for Health and Care Excellence (NICE): Recommendation for Diagnosis of Parkinson’s Disease
6.6.2.4. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s Disease
6.6.3. Diagnostic Algorithm
6.6.4. Differential Diagnosis
7. Patient Journey
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.2.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease
8.2.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease
8.2.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease
8.2.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease
8.3. Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM
8.4. The US
8.4.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US
8.4.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
8.4.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
8.4.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
8.5. EU4 and the UK
8.5.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
8.5.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
8.5.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
8.5.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
8.6.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
8.6.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
8.6.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
9. KOL Views10. Unmet Needs
11. Appendix
11.1. Acronyms and Abbreviations
11.2. Bibliography
12.3. Report Methodology
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of Parkinson’s Disease Epidemiology (2019-2032)
Table 2: Signs and Symptoms of Parkinson’s Disease
Table 3: Differential Diagnosis of Parkinsonism
Table 4: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM (2019-2032)
Table 5: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 6: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 7: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 8: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 9: Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 10: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 11: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 12: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 13: Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 14: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 15: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 16: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
List of Figures
Figure 1: Classification of Parkinson’s Disease
Figure 2: Clinical Manifestations in Parkinson’s Disease
Figure 3: Risk Factors Involved in Parkinson’s Disease
Figure 4: Genes Involved in Parkinson’s Disease
Figure 5: Mechanisms of Neurodegeneration in Parkinson’s Disease
Figure 6: QSBB Criteria for the Diagnosis of Parkinson’s Disease
Figure 7: MDS Clinical Diagnostic Criteria for Parkinson’s Disease
Figure 8: AAFP Diagnostic Algorithm for Parkinson’s Disease
Figure 9: Patient Journey
Figure 10: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM (2019-2032)
Figure 11: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 12: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 13: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 14: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 15: Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 16: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 17: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 18: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 20: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 21: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 22: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 23: Unmet Needs